Accessibility Menu
Black Diamond Therapeutics logo

Black Diamond Therapeutics

(NASDAQ) BDTX

Current Price$1.81
Market Cap$103.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-95%
5 Year-82%
1 Year-39%
1 Month+5%
Black Diamond Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.812026-07-15
Black Diamond Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.74%USD 1.902026-07-08
1 month+5.23%USD 1.722026-06-15
3 month-38.01%USD 2.922026-04-16
Year to date-25.51%USD 2.432025-12-31
1 year-38.64%USD 2.952025-07-15
3 year-62.68%USD 4.852023-07-14
5 year-81.97%USD 10.042021-07-16
Since inception-95.42%USD 39.482020-01-30

Black Diamond Therapeutics Financials at a Glance

Market Cap

$103.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$43.21M

EPS (TTM)

-$0.76

P/E Ratio

-2.39

Dividend

$0.00

Beta (Volatility)

1.56 (High)

Price

$1.81

Volume

855,782

Open

$1.78

Previous Close

$1.81

Daily Range

$1.76 - $1.82

52-Week Range

$1.60 - $4.94

Estimated Earnings Date

Aug 6, 2026

BDTX News

Foolcom-Featured.png

Black Diamond (BDTX) Q2 Loss Narrows 47%

Motley Fool Markets TeamAug 7, 2025
using a stethoscope listen to the heartbeat of patient (1)

Why Shares of Black Diamond Therapeutics Skyrocketed This Week

James HalleyJun 29, 2023
GettyImages-1129797106

How Did Last Week's IPOs Perform?

David HaenFeb 6, 2020

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Black Diamond Therapeutics

Black Diamond develops medicines for people with specific genetic cancers. Its main drugs aim to treat tumors that resist standard therapies. The company focuses on patients with brain and lung cancers who have limited treatment options.

Products and Services

  • Silevertinib (BDTX-1535): Brain-penetrant drug for lung and brain cancers with EGFR mutations; 0% of 2025 revenue.
  • BDTX-4933: Drug for cancers with BRAF, KRAS, and NRAS mutations; outlicensed, 100% of 2025 revenue from licensing.
  • BDTX-4876: Early-stage drug for cancers with FGFR2/3 mutations; no revenue contribution yet.
  • MAP Platform: Proprietary technology to discover new cancer drugs for genetically defined tumors.

Growth and Expansion

  • Outlicensed BDTX-4933 to Servier Pharmaceuticals in 2025, securing $70 million upfront.
  • Formed a technology partnership with OpenEye Scientific Software to enhance drug discovery.
  • Advanced silevertinib into Phase 2 trials for lung cancer in 2025.
  • Restructured operations and subleased facilities in late 2024 to cut costs.

What Makes Black Diamond Stand Out

Black Diamond targets groups of cancer mutations, not just single ones, using its MAP platform. Its drugs are designed to reach the brain, addressing cancers that spread there. The company funds its research by licensing drug candidates to larger partners.

Five Things You Need to Know

  • 2025 revenue was $70 million, up from $0 in 2024, all from licensing.
  • Operating expenses fell 27% to $57.5 million in 2025.
  • Net income reached $22.4 million in 2025, reversing a $69.7 million loss in 2024.
  • Cash and investments totaled $128.7 million at 2025 year-end.

Bottom Line

Black Diamond shifted from pure research to licensing, improving its financial position. The company remains focused on developing targeted cancer drugs for hard-to-treat tumors.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

21

CEO

Mark A. Velleca, MD, PhD

Website

www.blackdiamondtherapeutics.com

Headquarters

Cambridge, MA 02142, US

BDTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-36.37%

Return on Capital

15.17%

Return on Assets

-32.51%

Earnings Yield

-41.84%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$103.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

57.30M

Volume

855.78K

Avg. Volume

1.76M

Financials (TTM)

Gross Profit

-$113.00K

Operating Income

-$53.27M

EBITDA

-$38.09M

Operating Cash Flow

-$34.03M

Capital Expenditure

$0.00

Free Cash Flow

-$34.03M

Cash & ST Invst.

$118.26M

Total Debt

$17.88M

Black Diamond Therapeutics Performance Analysis

Black Diamond Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 70,000,000N/A
Black Diamond Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Black Diamond Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.51-27.7%
20232023-12-31USD -1.88-25.3%
20242024-12-31USD -1.27-32.5%
20252025-12-31USD 0.39N/A
Black Diamond Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-119.4%
Q32025-09-3021.1%
Q42025-12-31-73.3%
Q12026-03-3138.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$27.00K

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$103.72MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.94M

N/A

Employees

21

N/A

Net Income

-$9.04M

-116.0%

EBITDA

-$9.01M

-115.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$118.26M

-22.4%

Total Debt

$17.88M

-17.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$14.09M

-21.2%

Short Term Debt

$3.79M

+2.4%

Return on Assets

-32.51%

N/A

Return on Invested Capital

-44.99%

N/A

Free Cash Flow

-$10.23M

-119.2%

Operating Cash Flow

-$10.23M

-119.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AARDAardvark Therapeutics, Inc. Common Stock
$6.33-5.10%
TNYATenaya Therapeutics, Inc.
$0.84-0.66%
CRBUCaribou Biosciences, Inc.
$1.66-4.05%
IMRXImmuneering Corporation
$4.78-7.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%
ONDSOndas
$6.65-0.06%

Questions About BDTX

What is the current price of Black Diamond Therapeutics?

Black Diamond Therapeutics is trading at $1.81 per share.

What is the 52-week range for Black Diamond Therapeutics?

Over the past 52 weeks, Black Diamond Therapeutics has traded between $1.60 and $4.94.

How much debt does Black Diamond Therapeutics have?

As of the most recent reporting period, Black Diamond Therapeutics reported total debt of $17.88M.

How much cash does Black Diamond Therapeutics have on hand?

Black Diamond Therapeutics reported $30.07M in cash and cash equivalents in its most recent financial results.

What is Black Diamond Therapeutics’s dividend yield?

Black Diamond Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services